Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gsk Plc ADR
(NY:
GSK
)
33.96
+0.26 (+0.77%)
Official Closing Price
Updated: 7:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gsk Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
August 05, 2024
Moderna sustained a rare downgrade on Monday following its guidance cut for the year.
Via
Investor's Business Daily
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
August 02, 2024
Moderna cuts its 2024 sales forecast due to weaker demand for COVID-19 vaccines. Sales now expected between $3B-$3.5B, down from $4B. Analysts adjust price targets, citing competitive pressures from...
Via
Benzinga
Exposures
COVID-19
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
August 01, 2024
From
GSK plc
Via
Business Wire
British Pharma Giant GSK's Blockbuster Shingles And Respiratory Syncytial Virus Vaccine Q2 Sales Miss Expectations, Cuts Annual Vaccine Revenue Guidance
July 31, 2024
GSK reported Q2 sales of $9.95 billion, beating estimates of $9.66 billion. Specialty Medicine sales rose 20%, driven by strong HIV, Respiratory/Immunology, and Oncology performance. Core EPS of $1.10...
Via
Benzinga
Topics
Earnings
Exposures
Financial
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
July 29, 2024
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Is GSK a Top-Value Stock Right Now?
July 17, 2024
GSK, a multinational pharma company, scans as a bargain.
Via
The Motley Fool
Tech Stocks On Track For Best Session In 5 Months Ahead Of Fed Meeting; Small Caps Target Highest Close Since January 2022: What's Driving Markets Wednesday?
July 31, 2024
Tech stocks soared to their best session in five months on Wednesday, ahead of the highly anticipated Federal Open Market Committee (FOMC) meeting.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
GSK Beats Second-Quarter Views, Raises Outlook; But Shares Fall On Shingrix Miss
July 31, 2024
The company, however, raised its sales and earnings outlook for the year.
Via
Investor's Business Daily
Wall Street Remains On Track For AMD-Led Rebound Ahead Of Fed Decision, Meta Earnings: Analyst Says 'The Bull Tends To Remain' Despite Near-Time Volatility
July 31, 2024
Tech optimism is likely to abound on Wall Street as AI-levered stocks are feeding off the strength generated by Advanced Micro Devices, Inc.‘s (NASDAQ:AMD)
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
GSK Stock Earnings: GSK Beats EPS, Beats Revenue for Q2 2024
July 31, 2024
GSK stock results show that GSK beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
GSK's Top Selling Vaccine Can Potentially Reduce Dementia Risk, Research Suggests
July 26, 2024
New research suggests that GSK's Shingrix vaccine may reduce dementia risk, potentially revolutionizing treatment for older adults. The study, involving 200,000 people, indicates a significant...
Via
Benzinga
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
July 23, 2024
ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's benefit of less weight gain compared to Biktarvy, highlighting its efficacy and patient...
Via
Benzinga
3 Stocks Under $10 With the Potential for Massive Gains
July 22, 2024
Discover the growth potential of top small-cap stocks in the consumer finance, healthcare equipment and pharmaceutical industries.
Via
InvestorPlace
Top Research Reports For Apple, Lowe's & Shopify
July 17, 2024
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., Lowe's Companies, Inc., and Shopify Inc., as well as two micro-cap stocks MIND Technology, Inc., and...
Via
Talk Markets
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
July 17, 2024
European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed.
Via
Benzinga
Exposures
COVID-19
3 Top Cancer Treatment Stocks to Buy Now
July 17, 2024
These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term.
Via
InvestorPlace
Positive News is Driving This Cancer Drug Maker’s Stock Higher
July 15, 2024
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather
Via
MarketBeat
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
July 12, 2024
Pharma stocks can be great investments during times of growth and recession, and are made even better if the stock is undervalued.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season
July 11, 2024
From
GSK plc
Via
Business Wire
3 Dirt-Cheap Drug Developers With Blockbuster Potential
July 11, 2024
These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent.
Via
InvestorPlace
Health Officials Keep Close Eye On Bird Flu As It Infects Cows For The First Time
July 10, 2024
Avian influenza continues to spread among animals and has infected four dairy workers in the US. Concerns about human-to-human transmission are low.
Via
Benzinga
The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024
July 09, 2024
A full-throated bull market makes it tough to find undervalued stocks under $50, but these three could soon lead the charge higher.
Via
InvestorPlace
Pfizer's RSV Vaccine Abrysvo Clears Concerns Over Preterm Birth Risk, Safety For Pregnant Women, New Study Shows
July 08, 2024
Pfizer's RSV vaccine, Abrysvo, for pregnant women shows no increased risk of pre-term births, according to a study. Researchers found no significant difference in pre-term birth rates between...
Via
Benzinga
United Kingdom Stocks, ETFs To Watch After Keir Starmer, Labour Party Win
July 05, 2024
New leadership in the United Kingdom could make several sectors standout going forward. Here's what experts are saying after the election.
Via
Benzinga
Topics
ETFs
Upcoming Stock Spinoffs: Should You Pounce or Pass?
July 04, 2024
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in.
Via
InvestorPlace
CureVac Layoffs 2024: What to Know About the Latest CVAC Job Cuts
July 03, 2024
CureVac layoffs are coming for 30% of the vaccine company's employees as it prepares for a restructuring that will save it over 30% in costs.
Via
InvestorPlace
Topics
Workforce
Exposures
Layoff
CVAC Stock Alert: CureVac Pops on Licensing Deal With GSK
July 03, 2024
CureVac stock is up on Wednesday as CVAC investors react to the company signing a new 1.4 billion euro licensing agreement with GSK.
Via
InvestorPlace
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
July 03, 2024
GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gains full control of vaccine candidates for influenza and COVID-19, while...
Via
Benzinga
Exposures
COVID-19
3 No-Brainer Stocks to Buy With $300 Right Now for the Second Half of 2024
July 03, 2024
A modest amount of money can go a long way when it's put to work in highly innovative, game-changing businesses.
Via
The Motley Fool
Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
July 02, 2024
A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to proceed, with the companies needing Delaware Supreme Court approval to...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.